Innoviva (INVA) Cash from Financing Activities (2010 - 2026)

Innoviva (INVA) posted Cash from Financing Activities of -$20.1 million for Q1 2026, down 264.16% on a QoQ basis from $12.3 million in Q3 2025, and down 11108.74% year-over-year from N/an in Q1 2025.

Innoviva (INVA) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Innoviva's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$20.1 million for Q1 2026.

  • Quarterly Cash from Financing Activities fell 11108.74% year-over-year to -$20.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.4 million (up 77.05% YoY) and the FY2025 annual result came in at $8.6 million, up 163.56% from the prior year.
  • Cash from Financing Activities was -$20.1 million for Q1 2026 at Innoviva, down from $12.3 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $60.3 million in Q1 2022 and bottomed at -$157.2 million in Q3 2023.
  • A 5-year average of -$25.6 million and a median of -$9.2 million in 2023 frame the typical range for Cash from Financing Activities.
  • Annual changes were most pronounced in 2022 — Cash from Financing Activities soared 383.11% — and 2026, when it tumbled 11108.74%.
  • Innoviva's Cash from Financing Activities stood at -$45.6 million in 2022, then sank by 245.1% to -$157.2 million in 2023, then jumped by 91.08% to -$14.0 million in 2024, then soared by 187.49% to $12.3 million in 2025, then plunged by 264.16% to -$20.1 million in 2026.
  • Business Quant data shows INVA's Cash from Financing Activities at -$20.1 million in Q1 2026, $12.3 million in Q3 2025, and $1.2 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 Innoviva 1.57 Bn 969.11 Mn 75.83 Mn -20.15 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -20.15 Mn
Mar 31, 2026 -20.15 Mn
Sep 30, 2025 12.27 Mn
Sep 30, 2025 12.27 Mn
Jun 30, 2025 1.25 Mn
Jun 30, 2025 1.25 Mn
Mar 31, 2025 183,000.00
Mar 31, 2025 183,000.00
Sep 30, 2024 -14.03 Mn
Sep 30, 2024 -14.03 Mn
Jun 30, 2024 -5.07 Mn
Jun 30, 2024 -5.07 Mn
Mar 31, 2024 -9.17 Mn
Mar 31, 2024 -9.17 Mn
Sep 30, 2023 -157.25 Mn
Sep 30, 2023 -157.25 Mn
Jun 30, 2023 -9.21 Mn
Jun 30, 2023 -9.21 Mn
Mar 31, 2023 -136.96 Mn
Mar 31, 2023 -136.96 Mn